Hearing Loss Trial, Recruiting NCT06551857 Sponsor: Turku University Hospital Condition: Hearing Loss
Back to Hearing Loss

Hearing Loss Trial, Recruiting

NCT06551857
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You are willing and able to sign a written consent form agreeing to take part
  • You are a native Finnish speaker
  • Your hearing is normal for your age
  • (For people receiving treatment): You have been diagnosed with a cancer that will be treated with the goal of curing it, using one of the following: cisplatin chemotherapy, oxaliplatin chemotherapy, cisplatin chemotherapy combined with radiation to the head and neck area, or radiation therapy to the head and neck area

Who may not be able to join:

  • You are unable to sign a written consent form
  • You currently have, or have previously had, a significant ear or hearing condition that has affected or could have affected your hearing
  • You have a type of hearing loss where sound is blocked (conductive) or where one ear hears noticeably differently from the other (asymmetric), at any level of severity
  • You have severe hearing loss in the inner ear (sensorineural)
  • You have previously been treated for a cancer with chemotherapy or radiation therapy
  • You have previously taken medications known to be harmful to hearing
  • You have any significant illness or condition that the trial doctor believes could put you at risk or affect the trial results
  • You have any condition that the trial doctor believes would make it difficult for you to follow the trial requirements
  • (For people receiving treatment): You have an allergy or sensitivity to the trial medications or any of their ingredients
  • (For people receiving treatment): You are pregnant, breastfeeding, or planning to become pregnant during the trial

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 28 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Tytti Willberg, PhD, Turku University Hospital

Phone: +358 2 313 5979

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Turku University Hospital
Registry
ClinicalTrials.gov
Start date
2 October 2024
Est. completion
31 December 2029

Where this trial is recruiting

🇫🇮 Finland

Primary endpoints

Speech perception in noise

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov